Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Alexandra Lindsey Zune Djomkam; Charles Ochieng Olwal; Theodore Beyeme Sala; Lily Paemka

doi:10.3389/fonc.2020.01448

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Alexandra Lindsey Zune Djomkam, Charles Ochieng Olwal, Theodore Beyeme Sala, Lily Paemka

Department of Biochemistry, Cell And Molecular Biology

Research output: Contribution to journal › Comment/debate

51 Citations (Scopus)

Original language	English
Article number	1448
Journal	Frontiers in Oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.01448
Publication status	Published - 19 Aug 2020

Keywords

ACE2
COVID-19
SARS-CoV-2
TMPRSS2
coronavirus
prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2020.01448

Cite this

@article{c523d10b6b0549a78d27d32cf7905583,

title = "Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor",

keywords = "ACE2, COVID-19, SARS-CoV-2, TMPRSS2, coronavirus, prostate cancer",

author = "Djomkam, \{Alexandra Lindsey Zune\} and Olwal, \{Charles Ochieng\} and Sala, \{Theodore Beyeme\} and Lily Paemka",

year = "2020",

month = aug,

day = "19",

doi = "10.3389/fonc.2020.01448",

language = "English",

volume = "10",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Commentary

T2 - SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

AU - Djomkam, Alexandra Lindsey Zune

AU - Olwal, Charles Ochieng

AU - Sala, Theodore Beyeme

AU - Paemka, Lily

PY - 2020/8/19

Y1 - 2020/8/19

KW - ACE2

KW - COVID-19

KW - SARS-CoV-2

KW - TMPRSS2

KW - coronavirus

KW - prostate cancer

UR - https://www.scopus.com/pages/publications/85090152799

U2 - 10.3389/fonc.2020.01448

DO - 10.3389/fonc.2020.01448

M3 - Comment/debate

AN - SCOPUS:85090152799

SN - 2234-943X

VL - 10

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1448

ER -

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Keywords

UN SDGs

Access to Document

Other files and links

Cite this